Parent training may boost school success for latino kids with cancer
NCT ID NCT03178617
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a high-intensity parenting program can improve learning and school functioning in Latino children being treated for leukemia or lymphoma. About 214 parents and children will take part. Parents in the high-intensity group will receive extra training in skills that support learning, while the other group gets standard care. Researchers will measure changes in school performance, attention, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- educational intervention (parenting skills training program)
- What this could lead to
- If it works, this could show that training parents in specific skills helps children with cancer perform better in school and improves their quality of life.
- What could go wrong
- This is a behavioral study, not a drug trial, so results may be modest. It is also limited to Latino families, so findings may not apply to other groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
214 people
The number who actually took part.
- Started
-
Oct 2017
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
5 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * PARENT/CAREGIVER: Adult primary caregiver of children treated for leukemia or lymphoblastic lymphoma (LL) and daily contact with the child * PARENT/CAREGIVER: One or both parents self-identify as Hispanic/Latino and the primary participating parent/caregiver is monolingual or bilingual Spanish speaking * CHILD: Children treated for acute leukemia (e.g. acute lymphoblastic leukemia \[ALL\], acute myeloid leukemia \[AML\]), LL, or other types of leukemia (if treated intensively) aged 5-12 years and their parents/caregivers * CHILD: Child has completed cancer treatment and is up to 10 years post-treatment * CHILD: Child understands English and is enrolled in school (but can be bilingual) Exclusion Criteria: * History of major psychiatric condition (e.g. psychosis) in parent or child; severe neurodevelopmental disorder in child (e.g. Down's syndrome) * Recent or current participation in educational/behavioral intervention study with similar focus
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Orange County
Orange, California, 92868, United States
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an HDAC inhibitor wipe out residual leukemia cells?
- Can an experimental pill block a cancer-driving enzyme in hard-to-treat leukemia?
- Engineered immune cells aim to wipe out stubborn leukemia
- Two-Drug combo targets leukemia that outsmarted its first treatment
- Tweaking donor cells may shield older transplant patients from a dangerous complication
- Can a drug and donor cells stop leukemia from returning after transplant?